EvE Bio
@evebio.bsky.social
EvE Bio is a nonprofit biomed research institute in Durham NC. We're a Focused Research Org on a 5-year mission to create the discipline of "pharmome mapping." What that means: https://evebio.org. Watch here for job & data drop announcements
New data is live!! With 25 new kinases, we have a total of 420,497 drug-target interaction results! There are multiple ways to access the dataset 🧵
December 11, 2025 at 11:04 PM
New data is live!! With 25 new kinases, we have a total of 420,497 drug-target interaction results! There are multiple ways to access the dataset 🧵
It's the final day of our data release preview -- data will be posted tomorrow!
The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2
The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2
December 10, 2025 at 9:41 PM
It's the final day of our data release preview -- data will be posted tomorrow!
The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2
The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2
Day 5 of our kinase preview for our imminent data release: Emerging Oncology Targets
We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.
We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.
December 9, 2025 at 2:38 PM
Day 5 of our kinase preview for our imminent data release: Emerging Oncology Targets
We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.
We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.
It's data release week at EvE! Continuing with day 4 of our preview of the 25 kinases we'll release later this week, today's focus is on stress and survival pathways.
We're adding four kinases involved in cellular stress responses: MST2, MSK1, DAPK1, and ROS.
We're adding four kinases involved in cellular stress responses: MST2, MSK1, DAPK1, and ROS.
December 8, 2025 at 2:38 PM
It's data release week at EvE! Continuing with day 4 of our preview of the 25 kinases we'll release later this week, today's focus is on stress and survival pathways.
We're adding four kinases involved in cellular stress responses: MST2, MSK1, DAPK1, and ROS.
We're adding four kinases involved in cellular stress responses: MST2, MSK1, DAPK1, and ROS.
For the day 3 preview of EvE's kinase data release, the theme is calcium.
We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.
We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.
December 7, 2025 at 4:12 PM
For the day 3 preview of EvE's kinase data release, the theme is calcium.
We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.
We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.
Day 2 preview of EvE's kinase data release: The RSK Family
We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K.
These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.
We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K.
These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.
December 5, 2025 at 11:04 PM
Day 2 preview of EvE's kinase data release: The RSK Family
We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K.
These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.
We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K.
These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.
At EvE, we release data regularly, and our next release is coming up next week! We're adding 25 more kinases to our public drug-target interaction dataset.
Over the next 6 days, we'll preview what's coming. Day 1: The PKC Family
Over the next 6 days, we'll preview what's coming. Day 1: The PKC Family
December 5, 2025 at 1:21 AM
At EvE, we release data regularly, and our next release is coming up next week! We're adding 25 more kinases to our public drug-target interaction dataset.
Over the next 6 days, we'll preview what's coming. Day 1: The PKC Family
Over the next 6 days, we'll preview what's coming. Day 1: The PKC Family
We're excited to share several new developments. Our pharmome mapping dataset is now more accessible and integrated than ever, and the use cases we imagined are coming to life! 🧪
evebio.org/pharmome-dat...
Here's what's new: 🧵
evebio.org/pharmome-dat...
Here's what's new: 🧵
Putting Pharmome Data in Researchers' Hands : EvE Bio
We've been busy at EvE Bio these last two years establishing the largest available pharmome mapping dataset. Now it’s making its way into the world to drive real discoveries.
evebio.org
November 18, 2025 at 7:48 PM
We're excited to share several new developments. Our pharmome mapping dataset is now more accessible and integrated than ever, and the use cases we imagined are coming to life! 🧪
evebio.org/pharmome-dat...
Here's what's new: 🧵
evebio.org/pharmome-dat...
Here's what's new: 🧵
Reposted by EvE Bio
E11 Bio is excited to unveil PRISM technology for mapping brain wiring with simple light microscopes. Today, brain mapping in humans and other mammals is bottlenecked by accurate neuron tracing. PRISM uses molecular ID codes and AI to help neurons trace themselves.
Read more: e11.bio/blog/prism
Read more: e11.bio/blog/prism
October 1, 2025 at 2:16 PM
E11 Bio is excited to unveil PRISM technology for mapping brain wiring with simple light microscopes. Today, brain mapping in humans and other mammals is bottlenecked by accurate neuron tracing. PRISM uses molecular ID codes and AI to help neurons trace themselves.
Read more: e11.bio/blog/prism
Read more: e11.bio/blog/prism
Yikes.
WTF? I was quoted in this story but I have never spoken to the reporter nor would I have said those things. Is everything just generated by LLMs these days?
cosmosmagazine.com/earth/oceans...
cosmosmagazine.com/earth/oceans...
July 29, 2025 at 8:10 PM
Yikes.
Each of our bimonthly HTS data releases reveals previously unknown drug/off-target interactions, but some, like this snippet from last week's Release 5, showing that capsaicin is a highly selective agonist for the orphan nuclear receptor, ESRRB, deserves special note. 🧵 1/4 🧪
July 22, 2025 at 4:01 PM
Each of our bimonthly HTS data releases reveals previously unknown drug/off-target interactions, but some, like this snippet from last week's Release 5, showing that capsaicin is a highly selective agonist for the orphan nuclear receptor, ESRRB, deserves special note. 🧵 1/4 🧪
🧪Excited to learn that EvE Bio's unique pharmome-mapping data has been adopted by yet another biomedical reasoning model, Stanford's Biomni (biomni.stanford.edu). Awareness of and appreciation for our efforts is really snowballing. We're grateful to be of service to the community.
July 18, 2025 at 12:51 PM
🧪Excited to learn that EvE Bio's unique pharmome-mapping data has been adopted by yet another biomedical reasoning model, Stanford's Biomni (biomni.stanford.edu). Awareness of and appreciation for our efforts is really snowballing. We're grateful to be of service to the community.
🧪EvE will soon make our 1st announcement re: a potential drug repurposing opportunity open for licensing by orgs resourced to bring such things to the clinic. If your org would like early notice of such opptys, drop us a DM (or email list.signup@evebio.org) w/ name, org name, & business email.
July 14, 2025 at 2:29 PM
🧪EvE will soon make our 1st announcement re: a potential drug repurposing opportunity open for licensing by orgs resourced to bring such things to the clinic. If your org would like early notice of such opptys, drop us a DM (or email list.signup@evebio.org) w/ name, org name, & business email.
🧪 Thank-you to Abhi Mahajan for his long essay on EvE's efforts to map the pharmome. He did a good job of explaining a pretty arcane topic.
"EvE really exemplifies the thesis [that] smart people in biology should do more boring things." 🤠
www.owlposting.com/p/mapping-th...
"EvE really exemplifies the thesis [that] smart people in biology should do more boring things." 🤠
www.owlposting.com/p/mapping-th...
Mapping the off-target effects of every FDA-approved drug in existence (EvE Bio)
6.2k words, 29 minutes reading time
www.owlposting.com
July 14, 2025 at 2:02 PM
🧪 Thank-you to Abhi Mahajan for his long essay on EvE's efforts to map the pharmome. He did a good job of explaining a pretty arcane topic.
"EvE really exemplifies the thesis [that] smart people in biology should do more boring things." 🤠
www.owlposting.com/p/mapping-th...
"EvE really exemplifies the thesis [that] smart people in biology should do more boring things." 🤠
www.owlposting.com/p/mapping-th...
🧪 New toy! It's a robotic -20C freezer that can store 17,000 sample tubes, and upon command can spit out a rack containing just the tubes you've requested, in whatever pattern you want them. Everything is barcoded so the right sample always ends up in the right place. Or that's what they tell me.
June 6, 2025 at 1:25 PM
🧪 New toy! It's a robotic -20C freezer that can store 17,000 sample tubes, and upon command can spit out a rack containing just the tubes you've requested, in whatever pattern you want them. Everything is barcoded so the right sample always ends up in the right place. Or that's what they tell me.
🧪 Exciting to see EvE Bio's ever-expanding pharmome mapping dataset (data.evebio.org) cited as a source of training/test data for @futurehousesf.bsky.social's ether0 LLM, a new scientific reasoning model for chemistry. Preprint: storage.googleapis.com/aviary-publi...
Eve Bio: Pharmome Data
Browse/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products.
data.evebio.org
June 5, 2025 at 8:32 PM
🧪 Exciting to see EvE Bio's ever-expanding pharmome mapping dataset (data.evebio.org) cited as a source of training/test data for @futurehousesf.bsky.social's ether0 LLM, a new scientific reasoning model for chemistry. Preprint: storage.googleapis.com/aviary-publi...
🧪 EvE Bio's biggest public data release (#4) yet!
1.4k Rx drugs screened for 24 new potential off-targets including adrenergic, apelin, muscarinic, dopamine, gastrin-releasing, orexin, 5-HT, neuromedin, opioid, prostaglandin, sphingosine, somatostatin & neuromedin receptors. evebio.org/data
1.4k Rx drugs screened for 24 new potential off-targets including adrenergic, apelin, muscarinic, dopamine, gastrin-releasing, orexin, 5-HT, neuromedin, opioid, prostaglandin, sphingosine, somatostatin & neuromedin receptors. evebio.org/data
May 19, 2025 at 3:01 PM
🧪 EvE Bio's biggest public data release (#4) yet!
1.4k Rx drugs screened for 24 new potential off-targets including adrenergic, apelin, muscarinic, dopamine, gastrin-releasing, orexin, 5-HT, neuromedin, opioid, prostaglandin, sphingosine, somatostatin & neuromedin receptors. evebio.org/data
1.4k Rx drugs screened for 24 new potential off-targets including adrenergic, apelin, muscarinic, dopamine, gastrin-releasing, orexin, 5-HT, neuromedin, opioid, prostaglandin, sphingosine, somatostatin & neuromedin receptors. evebio.org/data
Reposted by EvE Bio
🧵 Today, IMPRINT, a pioneering new nonprofit initiative, is announcing $15 million in philanthropic funding to advance our work to decode the body's immune memory and uncover the causes of chronic diseases.
#Immunology #Biotech #BiotechResearch
#Immunology #Biotech #BiotechResearch
Press Release May 2025 — Imprint FRO
Imprint FRO launches with $15M in funding
www.imprint.org
May 15, 2025 at 1:01 PM
🧵 Today, IMPRINT, a pioneering new nonprofit initiative, is announcing $15 million in philanthropic funding to advance our work to decode the body's immune memory and uncover the causes of chronic diseases.
#Immunology #Biotech #BiotechResearch
#Immunology #Biotech #BiotechResearch
Wake up, babe. EvE Bio's data release #4 just dropped.
1.4k Rx drugs, 85 targets & counting:
237,490 combinations screened (mode/target/compound)
8 median agonists per target (potency < 1 uM)
31 median antagonists per target (potency < 1uM)
🧪Browse or DL (for non-commercial use) at evebio.org/data
1.4k Rx drugs, 85 targets & counting:
237,490 combinations screened (mode/target/compound)
8 median agonists per target (potency < 1 uM)
31 median antagonists per target (potency < 1uM)
🧪Browse or DL (for non-commercial use) at evebio.org/data
May 18, 2025 at 7:02 PM
Wake up, babe. EvE Bio's data release #4 just dropped.
1.4k Rx drugs, 85 targets & counting:
237,490 combinations screened (mode/target/compound)
8 median agonists per target (potency < 1 uM)
31 median antagonists per target (potency < 1uM)
🧪Browse or DL (for non-commercial use) at evebio.org/data
1.4k Rx drugs, 85 targets & counting:
237,490 combinations screened (mode/target/compound)
8 median agonists per target (potency < 1 uM)
31 median antagonists per target (potency < 1uM)
🧪Browse or DL (for non-commercial use) at evebio.org/data
Come work with us at EvE Bio in Durham, NC!
EvE's Assay Dev team is looking for a pharmacology scientist to develop new cell-based screening assays. While this is a temporary position (filling in for a scientist on family leave) it has potential to become permanent.
jobs.lever.co/convergentre...
EvE's Assay Dev team is looking for a pharmacology scientist to develop new cell-based screening assays. While this is a temporary position (filling in for a scientist on family leave) it has potential to become permanent.
jobs.lever.co/convergentre...
Convergent Research - Temporary Scientist, Receptor Pharmacologist in Cell-Based Assay Development
Durham NC’s EvE Bio is looking for a receptor biochemist/pharmacologist to join its assay development group at the scientist level. This is a temporary position (5 months) that has the potential to tr...
jobs.lever.co
May 5, 2025 at 4:44 PM
Come work with us at EvE Bio in Durham, NC!
EvE's Assay Dev team is looking for a pharmacology scientist to develop new cell-based screening assays. While this is a temporary position (filling in for a scientist on family leave) it has potential to become permanent.
jobs.lever.co/convergentre...
EvE's Assay Dev team is looking for a pharmacology scientist to develop new cell-based screening assays. While this is a temporary position (filling in for a scientist on family leave) it has potential to become permanent.
jobs.lever.co/convergentre...
Our data release #3, now live at data.evebio.org, adds 7 new nuclear receptors + 14 new 7TMs to our ever-growing list of human gene products screened against 1.4K FDA-approved drugs to ID off-targets, train AIs, repurpose drugs, and more. Enjoy! 🧪
April 1, 2025 at 7:52 PM
Our data release #3, now live at data.evebio.org, adds 7 new nuclear receptors + 14 new 7TMs to our ever-growing list of human gene products screened against 1.4K FDA-approved drugs to ID off-targets, train AIs, repurpose drugs, and more. Enjoy! 🧪
Work with us!
We seek a data scientist in the Research Triangle w/ great R & Shiny experience, comfort making technical decisions, and some scientific bkgd. This is a hybrid position requiring 2d/wk in our Durham office. 🧪https://jobs.lever.co/convergentresearch/ab999aec-2298-438a-bc54-d368b51cc6f4
We seek a data scientist in the Research Triangle w/ great R & Shiny experience, comfort making technical decisions, and some scientific bkgd. This is a hybrid position requiring 2d/wk in our Durham office. 🧪https://jobs.lever.co/convergentresearch/ab999aec-2298-438a-bc54-d368b51cc6f4
February 13, 2025 at 3:35 PM
Work with us!
We seek a data scientist in the Research Triangle w/ great R & Shiny experience, comfort making technical decisions, and some scientific bkgd. This is a hybrid position requiring 2d/wk in our Durham office. 🧪https://jobs.lever.co/convergentresearch/ab999aec-2298-438a-bc54-d368b51cc6f4
We seek a data scientist in the Research Triangle w/ great R & Shiny experience, comfort making technical decisions, and some scientific bkgd. This is a hybrid position requiring 2d/wk in our Durham office. 🧪https://jobs.lever.co/convergentresearch/ab999aec-2298-438a-bc54-d368b51cc6f4
🧪
EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org
For data drop announcements via email sign up at evebio.org
For data drop announcements via email sign up at evebio.org
Eve Bio: Pharmome Data
Browse/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products. Data Release 1 now live.
data.evebio.org
February 10, 2025 at 8:37 PM
🧪
EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org
For data drop announcements via email sign up at evebio.org
For data drop announcements via email sign up at evebio.org
Eve Bio: Pharmome Data
Browse/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products. Data Release 1 now live.
data.evebio.org
February 10, 2025 at 7:27 PM
EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org
For data drop announcements via email sign up at evebio.org
For data drop announcements via email sign up at evebio.org
Thank you Schmidt Initiative For Long Covid for moving the needle on clinical trials in search of therapeutics for LC. Repurposing Evusheld for LC is an interesting long-shot. 🤞
youtu.be/Nihzqamt5xY?...
youtu.be/Nihzqamt5xY?...
Are Monoclonal Antibodies a Possible Treatment for Long COVID? (E23) ft Prof Nancy Kilmas
YouTube video by Long Covid The Answers
youtu.be
December 8, 2024 at 5:46 PM
Thank you Schmidt Initiative For Long Covid for moving the needle on clinical trials in search of therapeutics for LC. Repurposing Evusheld for LC is an interesting long-shot. 🤞
youtu.be/Nihzqamt5xY?...
youtu.be/Nihzqamt5xY?...